This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.
CAR-T-cell therapy is a type of immunotherapy that involves collecting and using patients’ own immune cells to treat conditions including lymphoma, leukaemia and multiple myeloma.
with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndromes (MDS).
There are three main groups of blood cancer: leukaemia, lymphoma and myeloma. ... recommended for use as an additional treatment for patients aged 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
The prognosis for these patients has often been associated with worse overall outcomes and an increased risk of transformation to acute myeloid leukaemia (AML).
The European Commission (EC) has approved Otsuka Pharmaceutical and Astex Pharmaceuticals’s Inaqovi (oral decitabine and cedazuridine) as a monotherapy in certain acute myeloid leukaemia (AML) patients. ... AML is a rapidly progressing cancer of the
Fiona Hazel, chair of the Blood Cancer Alliance and chief executive officer of Leukaemia UK, said: "If you are living with blood cancer, you are likely to have a weakened immune
More from news
Approximately 95 fully matching, plus 449 partially matching documents found.
Furthermore, inhibitors of the c-ABl pathway, which are currently used to treat leukaemia, have been considered as potentially having neuroprotective effects in Parkinson’s disease.
myeloid leukaemia and potential application in other disease states.
large B-cell lymphoma, acute lymphoblastic leukaemia and other relapsed/ refractory haematologic cancer. ... tumour antigens, such as CD-19, CD20 and CD22, found predominantly in leukaemia and lymphoma.
The product underwent its first phase 1 trial test in January 2020 with a patient who was suffering from acute myeloid leukaemia.
symptoms including bladder/ bowel dysfunction, high blood pressure and leukaemia, and can reduce life expectancy by up to 15 years.
More from intelligence
Approximately 1 fully matching, plus 52 partially matching documents found.
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specialising in acute myeloid leukaemia.
breast cancer, leukaemia, lung cancer and prostate cancer.
In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
The filmmakers followed two leukaemia patients in first-in-human trials in the UK.
For instance, CLLSupport (a patient group for those living with chronic lymphocytic leukaemia (CLL)) ran in-person events for those with CLL pre-pandemic, and these events had a huge impact
Precision medicines already exist; imatinib works to treat leukaemia only when the cancer cells have a particular genetic makeup, Sotorasib targets a specific mutation in people with lung cancer to halt
For the Pip award, which aimed to promote the work of the Elimination of Leukaemia Fund (ELF) Mind and Body Service, Frontera was awarded for the ‘White Cell’.
The therapy was trialled in paediatric and young adult lymphoblastic leukaemia patients suffering from the most aggressive forms of the disease.
More from PMHub
Approximately 2 fully matching, plus 16 partially matching documents found.
No results were found
AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health...